Research use only. The information in this article is provided for educational and laboratory research purposes. BPC-157 is not approved by the FDA for human consumption, has not undergone Phase III clinical trials, and is not intended to diagnose, treat, cure, or prevent any disease. Nothing here constitutes medical advice.
If you’ve spent any time researching peptides, you’ve probably noticed something frustrating: most articles about BPC-157 dosage are either dangerously vague (“most users take 250-500 mcg per day”) or buried in jargon-heavy preprints. Neither helps a serious researcher understand what’s actually been studied, how the math works, or how to reconstitute a vial without wasting product.
This guide is the reference we wish existed when we started. It covers what BPC-157 actually is, how it behaves in the body, the dosage ranges used in published research, the math behind reconstituting a lyophilized vial, and the storage protocols that preserve potency. Everything is framed as research — because that’s the only context in which BPC-157 can be legally discussed.
What Is BPC-157?
BPC-157, short for Body Protection Compound 157, is a synthetic peptide composed of 15 amino acids:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
It is a partial sequence of a larger protein discovered in human gastric juice. The peptide was isolated and characterized by Professor Predrag Sikiric and his research group at the University of Zagreb in Croatia, who have published the majority of peer-reviewed BPC-157 literature over the past three decades.
What makes BPC-157 unusual among peptides is its stability in gastric acid. Most peptides are destroyed within minutes of contact with stomach acid, which is why insulin, GLP-1 agonists, and other peptide drugs must be injected. BPC-157 appears to retain at least some biological activity after oral administration — a property that has driven significant research interest.
Mechanism of Action
BPC-157 interacts with several biological pathways simultaneously, which is why the literature describes it as a “pleiotropic” compound — one with multiple downstream effects. The most well-documented mechanisms include:
- VEGFR2 upregulation: BPC-157 increases expression of vascular endothelial growth factor receptor 2, the primary driver of angiogenesis (new blood vessel formation). This is thought to underlie much of its observed tissue-repair activity.
- Nitric oxide (NO) system modulation: Research shows BPC-157 counteracts the negative effects of NO synthesis inhibition and may stabilize NO-mediated processes that influence vascular tone and inflammation.
- Growth hormone receptor expression: Studies on Achilles tendon fibroblasts show BPC-157 upregulates the growth hormone receptor, which may contribute to its observed effects on tendon healing in rodent models.
- Neurotransmitter interaction: Animal studies report interaction with dopaminergic, serotonergic, and GABA systems — though the clinical relevance of these findings remains unestablished.
Pharmacokinetics & Half-Life
Understanding the pharmacokinetics of BPC-157 helps explain why research protocols typically use frequent, small doses rather than large weekly doses.
| Property | Reported Value |
|---|---|
| Molecular weight | 1419.5 Da |
| Plasma half-life (IV, rat) | ~30 minutes |
| Plasma half-life (subcutaneous, rat) | ~4 hours (estimated) |
| Oral bioavailability | Unusual stability vs other peptides — exact figure unestablished |
| Route in most studies | Intraperitoneal (rodents); subcutaneous and oral in others |
The relatively short plasma half-life is why most published protocols administer BPC-157 once or twice daily rather than as a weekly bolus. The compound’s biological effects appear to persist longer than circulating drug levels would suggest, possibly because the downstream signaling pathways (angiogenesis, growth factor expression) have their own time courses.
Research Dosage Protocols
The following table summarizes dosage ranges that appear in the published literature. These figures are reported research doses — not recommendations. Most studies were conducted in rodent models, and direct extrapolation to humans is scientifically inappropriate.
| Application (research context) | Reported dose range | Frequency | Route |
|---|---|---|---|
| General tissue-repair research | 10 mcg/kg body weight | Once or twice daily | Subcutaneous (rodent) |
| Tendon healing studies | 10 mcg/kg | Once daily | Subcutaneous or intraperitoneal |
| GI ulcer research | 10 mcg/kg to 10 ng/kg | Once or twice daily | Oral or intraperitoneal |
| Localized injection research | Varies (site-specific) | Per protocol | Subcutaneous near target tissue |
For perspective: at the 10 mcg/kg figure cited in many rodent studies, a 70 kg adult would extrapolate to roughly 700 mcg per day. This is significantly higher than the 250-500 mcg range commonly discussed in non-academic forums. The discrepancy reflects how rodent pharmacology often does not translate linearly to humans, and why human-equivalent dosing is an open research question.
Reconstitution Guide
BPC-157 ships as a lyophilized (freeze-dried) powder. Before it can be used in research, it must be reconstituted with sterile bacteriostatic water (BAC water). The math for doing this correctly is straightforward but critical for accurate dosing.
The Core Formula
Concentration (mcg/mL) = Total peptide (mcg) ÷ Volume of BAC water added (mL)
From there, the volume needed for any specific dose is:
Volume to draw (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL)
Common Reconstitution Scenarios
| Vial size | BAC water added | Concentration | Volume for 250 mcg dose | Units on insulin syringe (U-100) |
|---|---|---|---|---|
| 5 mg | 2 mL | 2,500 mcg/mL | 0.10 mL | 10 units |
| 5 mg | 3 mL | 1,667 mcg/mL | 0.15 mL | 15 units |
| 10 mg | 2 mL | 5,000 mcg/mL | 0.05 mL | 5 units |
| 10 mg | 3 mL | 3,333 mcg/mL | 0.075 mL | ~8 units |
| 10 mg | 5 mL | 2,000 mcg/mL | 0.125 mL | ~13 units |
The general principle: more BAC water means a less concentrated solution and a larger volume per dose. Researchers often prefer 2 mL or 3 mL reconstitution because the resulting volume per dose is easy to read on an insulin syringe (5-15 units range), reducing measurement error.
Reconstitution Procedure
- Allow the lyophilized vial to reach room temperature.
- Wipe the rubber stopper of both the BAC water and peptide vials with an alcohol swab.
- Draw the calculated volume of BAC water into a sterile syringe.
- Insert the needle into the peptide vial at an angle and slowly inject the BAC water down the side of the vial — not directly onto the lyophilized powder.
- Do not shake. Gently swirl until the powder fully dissolves (typically 1-2 minutes).
- Label the vial with the reconstitution date and concentration.
- Store immediately under refrigeration (2-8 °C).
Storage Best Practices
| State | Temperature | Stable for |
|---|---|---|
| Lyophilized (unopened) | 2-8 °C (refrigerated) | 24+ months |
| Lyophilized (room temp shipping) | Up to 25 °C | Days to weeks (acceptable for transit) |
| Reconstituted | 2-8 °C (refrigerated, dark) | ~30 days at typical concentrations |
| Frozen lyophilized | -20 °C | Indefinite for research purposes |
Two practical notes from the literature: repeated freeze-thaw cycles degrade peptide integrity, so reconstituted product should not be frozen and re-thawed. And light exposure should be minimized — amber vials or aluminum foil wrap are common in laboratory settings.
Key Studies in the Peer-Reviewed Literature
A non-exhaustive sample of frequently cited primary research on BPC-157:
- Sikiric et al. (2018) — “Stable gastric pentadecapeptide BPC 157 as therapy in clinical trials and clinical practice” (Current Pharmaceutical Design). A review of accumulated preclinical and limited clinical evidence by the original discovery group.
- Chang et al. (2011) — “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration” (Journal of Applied Physiology). Often cited in tendon-research contexts.
- Krivic et al. (2006) — Studies on BPC-157 effects in intestinal anastomosis and GI repair models in rats.
- Seiwerth et al. (2014) — Reviews mechanism work on BPC-157 and the nitric oxide system.
- Hsieh et al. (2017) — Investigations of BPC-157 effects on vascular endothelial cells, supporting the VEGFR2-pathway model.
It is important to note that the overwhelming majority of BPC-157 research has been conducted in rodent and in-vitro models. Large, well-controlled human clinical trials have not been published. Anyone reviewing this literature should weigh that limitation carefully.
Reported Side Effects in Research
Published animal research consistently describes BPC-157 as well-tolerated, with no LD-50 (lethal dose for 50% of subjects) established at the doses tested. However, “well-tolerated in rodents” is not equivalent to “safe in humans.” The long-term safety profile of BPC-157 in human subjects is not established by published clinical trials.
Anecdotal reports outside of formal research describe occasional injection-site reactions, transient fatigue, and mild headaches. Because these reports come from outside controlled study conditions, they cannot reliably be attributed to the peptide itself.
Sourcing Research-Grade BPC-157
The single most important variable in any BPC-157 research protocol is the quality of the starting material. Peptides synthesized to lower than 99% purity contain unknown impurities — often truncated sequences, incomplete synthesis byproducts, or residual solvents. These impurities introduce uncontrolled variables that compromise the validity of any downstream finding.
Vital Aminos publishes a third-party HPLC and mass spectrometry Certificate of Analysis for every batch of BPC-157 10mg and the combined BPC-157 / TB-500 blend. Researchers investigating combined healing protocols often look at the Healing and Repair Bundle, which includes BPC-157, GHK-Cu, and TB-500 at a discount versus individual purchase.
Frequently Asked Questions
What is the typical research dose of BPC-157?
Published rodent studies typically use 10 mcg/kg body weight, administered subcutaneously or intraperitoneally, once or twice daily. Direct human-equivalent extrapolation is scientifically inappropriate, and human dosing remains an open research question.
How is BPC-157 reconstituted?
Lyophilized BPC-157 is reconstituted with bacteriostatic water. For a 10 mg vial, adding 2 mL of BAC water produces a 5,000 mcg/mL solution — meaning a 250 mcg dose corresponds to 0.05 mL, or 5 units on a standard U-100 insulin syringe.
How long does reconstituted BPC-157 last?
Stored at 2-8 °C in a dark container, reconstituted BPC-157 retains potency for approximately 30 days. Lyophilized vials, unreconstituted, are stable for 24+ months refrigerated and indefinitely when frozen.
Can BPC-157 be taken orally?
BPC-157 is unusual among peptides for its stability in gastric juice, which has driven research interest in oral administration. However, comparative bioavailability versus subcutaneous administration in humans is not well established by published clinical trials.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any human use. It is sold strictly for laboratory research and is banned by the World Anti-Doping Agency (WADA) for use in competitive athletics.
This article is provided for research and educational purposes only. The information presented summarizes published peer-reviewed research and is not intended to diagnose, treat, cure, or prevent any disease. BPC-157 is a research peptide and has not been evaluated by the FDA for human use. Always consult applicable institutional guidelines before conducting any research involving peptide compounds.